Agios Pharma up 15% premarket on news that collaboration partner Celgene to file NDA for AG-221 in AML by year end

• Agios Pharmaceuticals (NASDAQ:AGIO) is up 15% premarket on increased volume in response to the announcement that collaboration partner Celgene (NASDAQ:CELG) plans to file a New Drug Application (NDA) with the FDA by year end seeking approval of Agios' AG-221 for the treatment of patients with advanced blood cancers who have a mutation in a protein called isocitrate dehydrogenase-2 (IDH2). Celgene will be discussing its plans for the NDA today at the Citi 11th Annual Biotech Conference in Boston.
• The data supporting the NDA was generated in a Phase 1/2 study in patients with IDH2 mutation-positive acute myeloid leukemia (AML). AG-221 (enasidenib) inhibits IDH2.
• In May, Agios and Celgene announced a collaboration to discover, develop and commercialize novel immuno-oncology therapies based on Agios' cellular metabolism research platform. The new partnership followed the expiration of the discovery phase of their 2010 agreement, which includes AG-221.
• Previously: Celgene and Agios Pharma team up in immuno-oncology; Agios up 4% after hours (May 17)